Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Changes in mRNA abundance drive shuttling of RNA binding proteins, linking cytoplasmic RNA degradation to transcription.

Gilbertson S, Federspiel JD, Hartenian E, Cristea IM, Glaunsinger B.

Elife. 2018 Oct 3;7. pii: e37663. doi: 10.7554/eLife.37663.

2.

Orthologous CRISPR-Cas9 enzymes for combinatorial genetic screens.

Najm FJ, Strand C, Donovan KF, Hegde M, Sanson KR, Vaimberg EW, Sullender ME, Hartenian E, Kalani Z, Fusi N, Listgarten J, Younger ST, Bernstein BE, Root DE, Doench JG.

Nat Biotechnol. 2018 Feb;36(2):179-189. doi: 10.1038/nbt.4048. Epub 2017 Dec 18.

3.

The structural basis of flagellin detection by NAIP5: A strategy to limit pathogen immune evasion.

Tenthorey JL, Haloupek N, López-Blanco JR, Grob P, Adamson E, Hartenian E, Lind NA, Bourgeois NM, Chacón P, Nogales E, Vance RE.

Science. 2017 Nov 17;358(6365):888-893. doi: 10.1126/science.aao1140.

4.

Genetic and Proteomic Interrogation of Lower Confidence Candidate Genes Reveals Signaling Networks in β-Catenin-Active Cancers.

Rosenbluh J, Mercer J, Shrestha Y, Oliver R, Tamayo P, Doench JG, Tirosh I, Piccioni F, Hartenian E, Horn H, Fagbami L, Root DE, Jaffe J, Lage K, Boehm JS, Hahn WC.

Cell Syst. 2016 Sep 28;3(3):302-316.e4. doi: 10.1016/j.cels.2016.09.001.

5.

Genetic screens and functional genomics using CRISPR/Cas9 technology.

Hartenian E, Doench JG.

FEBS J. 2015 Apr;282(8):1383-93. doi: 10.1111/febs.13248. Epub 2015 Mar 16. Review.

6.

Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation.

Doench JG, Hartenian E, Graham DB, Tothova Z, Hegde M, Smith I, Sullender M, Ebert BL, Xavier RJ, Root DE.

Nat Biotechnol. 2014 Dec;32(12):1262-7. doi: 10.1038/nbt.3026. Epub 2014 Sep 3.

7.

Genome-scale CRISPR-Cas9 knockout screening in human cells.

Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelson T, Heckl D, Ebert BL, Root DE, Doench JG, Zhang F.

Science. 2014 Jan 3;343(6166):84-87. doi: 10.1126/science.1247005. Epub 2013 Dec 12.

8.

The clinical use of gelatin solution intravenously.

HARTENIAN E.

Bull Georgetown Univ Med Cent. 1950 Oct-Nov;4(3):69-70. No abstract available.

PMID:
24539239

Supplemental Content

Loading ...
Support Center